Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback